Dithiazanine

Summary

Dithiazanine (CHEMBL1185568) is an approved small-molecule anthelminthic drug.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 391.6 Da · C23H23N2S2+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1185568
Name	Dithiazanine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	10579
ChEBI	CHEBI:52787
Molecular formula	C23H23N2S2+
Molecular weight	391.6
InChIKey	FYXWDSGGZAMYFZ-UHFFFAOYSA-N

SMILES: CCN1C2=CC=CC=C2SC1=CC=CC=CC3=[N+](C4=CC=CC=C4S3)CC

IUPAC name: 3-ethyl-2-[5-(3-ethyl-1,3-benzothiazol-3-ium-2-yl)penta-2,4-dienylidene]-1,3-benzothiazole

ChEBI definition: A cationic C3-cyanine dye with 3-ethylbenzothiazol-2-yl groups at both ends.

Pharmacological roles (ChEBI): fluorochrome, anthelminthic drug.

Also known as: Dithiazanine, Dithiazanine cation, Dithiazanine ion, SID50125814, SID124893646, SID50125815, COMPOUND-01748

Parent form; salt/anhydrous children: CHEMBL421701, CHEMBL2357179

Patent coverage: 53 distinct patent families (123 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 97 (79%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Nuclear receptor ROR-gamma, RecQ-like DNA helicase BLM, 4’-phosphopantetheinyl transferase ffp, Menin/Histone-lysine N-methyltransferase MLL, Huntingtin.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 6 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
MEN1	5.45	Potency	3548	nM	CHEMBL_ACT_4591395
HTT	5.4	Potency	3981	nM	CHEMBL_ACT_3755351
P51450	5.4	Potency	3981	nM	CHEMBL_ACT_4116318
P51450	5.15	Potency	7080	nM	CHEMBL_ACT_4971895

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).